Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORION-PEDS-OLE: Long-term Safety and Tolerability of Inclisiran in Pediatric HeFH or HoFH
NCT05682378Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Feb 2023
- Primary completion
- Mar 2032
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 26
01
Overview
Phase 3, open-label, single-arm trial of inclisiran in familial hypercholesterolemia (FH), sponsored by Novartis. Primary endpoint: Treatment-Emergent Adverse Events and Serious Adverse Events at 1080 days. Started Feb 2023; status: recruiting.
02
Drugs
inclisiran
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NCT05682378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05682378.